[Tumor necrosis factor alpha and the heart--can heart diseases be treated by neutralizing cytokines?].
Ylitalo
K
K
Department of Biological Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel. kari.ylitalo@oulu.fi
Peuhkurinen
K
K
D000818:Animals; D000068800:Etanercept; D006331:Heart Diseases / Q000188:drug therapy / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009206:Myocardium / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000627:therapeutic use
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept